Compare Dow Inc (DOW) vs Novavax Inc (NVAX) Price & Performance

DOW trades at $30.64, up 0.2% with a bullish technical signal and recent earnings beats. The company shows declining revenue trends from $56.9B in 2022 to $40.0B in 2025, with negative net income margins. Analyst consensus is mixed with 33% buy ratings and a $35.11 price target, representing 15% upside. Recent dividend payment of $0.35 provides income support amid challenging fundamentals.

While technical indicators suggest near-term strength, fundamental challenges persist with negative profitability and declining cash flow. The stock offers potential upside to analyst targets but faces execution risks in a competitive chemical sector. Dividend yield provides some cushion, but investors need sustained operational improvement for meaningful long-term returns.

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.